Predictive and prognostic factors in HCC patients treated with sorafenib

Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Vito Longo, Angela Calabrese, Antonella Argentiero, Sabina Delcuratolo, Antonio Giovanni Solimando, Andrea Casadei-Gardini, Nicola Silvestris

Research output: Contribution to journalReview articlepeer-review


Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.

Original languageEnglish
Article number707
JournalMedicina (Lithuania)
Issue number10
Publication statusPublished - Oct 2019


  • Hepatocellular carcinoma
  • Predictive factors
  • Prognostic factors
  • Sorafenib

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Predictive and prognostic factors in HCC patients treated with sorafenib'. Together they form a unique fingerprint.

Cite this